[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 3 of about 3
1. Zhao TT, Li JG, Li YM: [Performance of 18F-FDG PET/CT in the detection of primary breast cancer and staging of the regional lymph nodes]. Zhonghua Zhong Liu Za Zhi; 2007 Mar;29(3):206-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Performance of 18F-FDG PET/CT in the detection of primary breast cancer and staging of the regional lymph nodes].
  • OBJECTIVE: To evaluate the performance of 18F-FDG PET/CT in the detection of primary breast cancer, and the staging of regional lymph nodes.
  • METHODS: Twenty four females with highly suspected breast cancer, underwent PET/CT imaging of the breast preoperatively.
  • Three nuclear medicine physicians analyzed the image and made the diagnosis.
  • 32 breast lesions were evaluated by histology, revealing 25 breast carcinomas and 7 benign pathological changes.
  • 23 patients had histological diagnosis of the breast tumor and regional lymph nodes.
  • RESULTS: 20 of 25 breast carcinomas were successfully diagnosed by FDG-PET/CT.
  • No Tis breast carcinoma was detected.
  • 75.0% of T1 breast carcinomas were detected, and with 85.7% of stage T2, 100.0% of T3.
  • CONCLUSION: As a noninvasive technique, FDG PET/CT appears to be a useful method in staging patient with breast cancer, especially in cases in which the lesion is hard to predict by routine examination.
  • In the detection of breast lesions, PET/CT doesn't seem to have a high sensitivity, especially in early stage breast cancers.
  • The high cost and the space resolution limit its use as a routine diagnostic method of breast cancer.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma, Ductal, Breast / diagnosis. Lymph Nodes / pathology. Positron-Emission Tomography / methods. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Adult. Aged. Female. Fibroadenoma / diagnosis. Fibroadenoma / pathology. Fluorodeoxyglucose F18. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Reproducibility of Results. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17649638.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


2. Blohmer JU, Reinhardt M, Schmalisch G, Lichtenegger W, Hausschild M, K├╝mmel S, Fischer T, Ohlinger R, Thomas A: Videodensitometry in the examination of focal breast lesions after injection of an ultrasound contrast agent. Anticancer Res; 2006 Mar-Apr;26(2C):1691-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Videodensitometry in the examination of focal breast lesions after injection of an ultrasound contrast agent.
  • BACKGROUND: The present investigation aimed at assessing the possibility of distinguishing between malignant and benign breast lesions by measuring the signal intensity in vessels of the suspect lesions over time after administration of the ultrasound contrast agent Levovist.
  • MATERIALS AND METHODS: Levovist was administered intravenously to 21 patients with breast cancer and 12 patients with a benign breast lesion.
  • RESULTS: The differences between the benign and the malignant lesions for the parameters T(max) and T(90%) were statistically significant.
  • The malignant foci showed a significantly more rapid in-flow of the contrast agent (p = 0.006) than the benign lesions.
  • The wash-in wash-out time for Levovist was significantly shorter for the malignant lesions than for the benign lesions (p = 0.02).
  • The specificity and sensitivity made a more precise differentiation between benign and malignant tumors possible.
  • CONCLUSION: The use of a contrast agent in Doppler ultrasound enhances the diagnostic reliability in distinguishing between malignant and benign lesions, justifying the use of a contrast agent with a high specificity (92%) such as Levovist.
  • It is possible that the combination of Levovist and videodensitometry will make it possible to increase the specificity of breast cancer diagnosis.
  • [MeSH-major] Breast Neoplasms / diagnosis. Densitometry / methods. Polysaccharides. Video Recording / methods
  • [MeSH-minor] Contrast Media. Female. Fibroadenoma / blood supply. Fibroadenoma / diagnosis. Fibroadenoma / pathology. Humans. Middle Aged. Neoplasm Staging. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16617563.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Polysaccharides; 127279-08-7 / SHU 508
  •  go-up   go-down


Advertisement
3. Bernardes JR Jr, Seixas MT, Lima GR, Marinho LC, Gebrim LH: The effect of tamoxifen on PCNA expression in fibroadenomas. Breast J; 2003 Jul-Aug;9(4):302-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • For almost three decades, tamoxifen has been used in the adjuvant treatment of breast cancer.
  • Since a fibroadenoma is a benign hormone-dependent neoplasm which contains estrogen receptor (ER) levels higher than in the mammary lobule, an evaluation of the effect of this drug on the proliferative activity of both the epithelium and the stroma of fibroadenomas in premenopausal women following the administration of 10 or 20 mg/day over 22 days was proposed.
  • Forty women with fibroadenoma were selected for a randomized double-blind trial.
  • The fibroadenoma was fixed in 10% formaldehyde solution and stained with hematoxylin and eosin and then processed through immunohistochemical reaction (PC-10, DAKO code number M879, Denmark A/S).
  • It was found that tamoxifen reduced the expression of PCNA in the epithelium and the stroma of the fibroadenoma.
  • [MeSH-major] Breast Neoplasms / metabolism. Estrogen Antagonists / pharmacology. Fibroadenoma / metabolism. Neoplasms, Hormone-Dependent / metabolism. Proliferating Cell Nuclear Antigen / metabolism. Tamoxifen / pharmacology
  • [MeSH-minor] Adolescent. Adult. Chemotherapy, Adjuvant. Double-Blind Method. Drug Administration Schedule. Epithelium / drug effects. Epithelium / metabolism. Estradiol / blood. Female. Humans. Premenopause. Progesterone / blood. Sex Hormone-Binding Globulin / metabolism. Stromal Cells / drug effects. Stromal Cells / metabolism. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. ESTRADIOL .
  • Hazardous Substances Data Bank. PROGESTERONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12846865.001).
  • [ISSN] 1075-122X
  • [Journal-full-title] The breast journal
  • [ISO-abbreviation] Breast J
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Estrogen Antagonists; 0 / Proliferating Cell Nuclear Antigen; 0 / Sex Hormone-Binding Globulin; 094ZI81Y45 / Tamoxifen; 4G7DS2Q64Y / Progesterone; 4TI98Z838E / Estradiol
  •  go-up   go-down






Advertisement